Ucb S.a.

Ucb Societe Anonyme

Jean Gobert

Eric Cossement

Guy Bodson

Ernst Wulfert

Jean-Pierre Jules Geerts

Philippe Michel

Berend Jan Van Keulen

Solo Goldstein

Corneliu Giurgea

Alex Bollen

Roland Boydens

Alma Gower

Guy Dodson

Jacques Mathieu

Enantiomers of 1&lsqb;(4-chloro-phenyl) phenylmethyl&rsqb;-4-&lsqb;(4-methylphenyl) sulfony&rsqb;piperazine

Levorotatory and dextrorotatory enantiomers of 1-�(4-chlorophenyl)phenylmethyl!-4-�(4-methylphenyl)sulfonyl!piperazine of the formula ##STR1## their preparation and use for the preparation of substantially optically pure enantiomers of 1-�(4-chlorophenyl)phenylmethyl!piperazine, which are themselves valuable intermediate products for the preparation of optically active therapeutic compounds having a very high degree of optical purity.

Enantiomers of 1-�(4-chlorophenyl)phenylmethyl!-4-�(4-methylphenyl)

Enantiomers of 1-�(4-chlorophenyl)phenylmethyl!-�(4-methylphenyl)sulfonyl!p

Levorotatory and dextrorotatory enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl)sulfonyl]piperazine of the formula ##STR1## their preparation and use for the preparation of substantially optically pure enantiomers of 1-[(4-chlorophenyl)phenylmethyl]piperazine, which are themselves valuable intermediate products for the preparation of optically active therapeutic compounds having a very high degree of optical purity.

Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl)

A method is disclosed for the treatment of anxiety in a patient in need thereof, by administering to said patient an effective amount of (S)-(-)-.alpha.-ethyl-2-oxo-1-pyrrolidineacetamide of the formula ##STR1##

Treatment of anxiety with the aid of

New 2-hydroxyl-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides as well as their salts, having the formula ##STR1## wherein R.sub.1 is hydrogen or an alkyl radical having 1 to 4 carbon atoms,

Hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzenecarboximidamides and their

New substituted cyclopropylamino-1,3,5-triazines having the formula ##STR1## wherein R.sub.1 is C.sub.1 -C.sub.3 -alkyl, C.sub.3 -C.sub.5 -cycloalkyl or C.sub.1 -C.sub.3 -alkyl-C.sub.3 -C.sub.5 -cycloalkyl

Substituted cyclopropylamino-1,3,5-triazines

The present invention provides recombinant DNA sequences comprising a sequence which codes for human proapolipoprotein A-I wherein part of the natural coding sequence has been replaced by a DNA fragment coding for the same amino acids but consisting of a different nucleotide sequence such as to reduce or prevent formation of hairpins, cloning and expression vectors containing these DNA sequences, cell cultures or microorganisms transformed with these expression vectors and processes using the same for the production of proapolipoprotein A-I.

Expression of human proapolipoprotein A-I

New 2-amino-4-morpholino-6-propyl-1,3,5-triazines having the formula ##STR1## wherein R.sub.1 is hydrogen, alkyl, aralkyl or acetyl,

2-amino-4-morpholino-6-propyl-1,3,5-triazines

A method for the treatment of cognitive and behavioral disorders associated with aging and with dementia syndromes, for example senile dementia, Alzheimer's type, by administering a 2-amino-4-morpholino-6-propyl-1,3,5-triazine of the formula ##STR1## in which R.sub.1 =hydrogen, alkyl, aralkyl or acetyl, R.sub.2 =hydrogen, hydroxyl, alkyl, hydroxyalkyl, alkoxyalkyl, dialkylamino, aryl-hydroxyalkyl, (hydroxycycloalkyl)alkyl, alkanoyloxyalkyl, benzoyloxyalkyl, phenylacetyloxyalkyl, aminocarbonyloxyalkyl, COR.sub.3, where R.sub.3 =alkyl, aryl, halogenoaryl, alkylaryl, alkoxyaryl, aralkyl or aryloxy, CONR.sub.4 R.sub.5, where R.sub.4 and R.sub.5 =hydrogen or alkyl, or R.sub.1 and R.sub.2 form an alkyleneimino substituted by hydroxyalkyl, and in addition when R.sub.1 =acetyl, R.sub.2 =acetoxyalkyl, or a salt thereof.

Treatment of cognitive and behavioral disorders associated with aging

(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide, its preparation and pharmaceutical compositions containing the same. It can be prepared either by reacting (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetic acid successively with an alkyl haloformate and with ammonia, or, by cyclizing an (S)-2-amino-butanamide of the formula X--CH.sub.2 CH.sub.2 --Y--NHCH(C.sub.2 H.sub.5)CONH.sub.2 wherein Y is a --CH.sub.2 -- radical when X represents a ZOOC-- radical and Y is a --CO-- radical when X represents a HalCH.sub.2 -- radical, Z being a C.sub.1 -C.sub.4 alkyl radical and Hal a halogen atom. This laevorotatory enantiomer has been found to have significantly higher protective activity against hypoxia and ischemia than the corresponding racemate.

(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide

New substituted 1-(1H-imidazol-4-yl)alkyl-benzamides and their salts, processes for the preparation thereof and pharmaceutical compositions. These compounds have the formula ##STR1## wherein R.sub.1, R.sub.2 =hydrogen or C.sub.1 -C.sub.4 -alkyl,

Substituted 1-(1H-imidazol-4-yl)alkyl-benzamides as anti-ischemics and

(R)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide, its preparation and pharmaceutical compositions containing the same. It can be prepared either by reacting (R)-alpha-ethyl-2-oxo-1-pyrrolidineactic acid successively with an alkyl haloformate and with ammonia, or, by cyclizing an (R)-2-amino-butanamide of the formula X--CH.sub.2 CH.sub.2 --Y--NHCH (C.sub.2 H.sub.5)CONH.sub.2 wherein Y is a --CH.sub.2 --radical when X represents a ZOOC--radical and Y is a --CO--radical when X represents a HalCH.sub.2 --radical, Z being a C.sub.1 -C.sub.4 alkyl radical and Hal a halogen atom. This dextrorotatory enantiomer has been found to have significantly higher mnemic activity and lower toxicity than the corresponding racemate.

(R)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide compositions

(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide, its preparation and pharmaceutical compositions containing the same. It can be prepared either by reacting (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetic acid successively with an alkyl haloformate and with ammonia, or, by cyclizing an (S)-2-amino-butanamide of the formula X--CH.sub.2 CH.sub.2 -NHCH (C.sub.2 H.sub.5)CONH.sub.2 wherein Y is a --CH.sub.2 --radical when X represents a ZOOC--radical and Y is a --CO-- radical when X represents a HalCH.sub.2 --radical, Z being a C.sub.1 -C.sub.4 alkyl radical and Hal a halogen atom. This laevorotatory enantiomer has been found to have significantly higher protective activity against hypoxia and ischemia than the corresponding racemate.

Growing community of inventors

Brussels, Belgium

Jean Gobert